TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9454185

Group type: EXPERIMENTAL
Intervention: Radical neck dissection (group A)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Non-neoplastic ORL diseases (group B)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Patients examined shorter than one year after operation
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Total laryngectomy patients
Number of subjects: 87
Study: 2095759

Group type: EXPERIMENTAL
Intervention: Elastic stockings and stanozolol
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Elastic stockings and surgical ligation of incompetent superficial veins
Number of subjects: 68

Group type: COMPARATOR
Intervention: Elastic stockings only
Number of subjects: 68
Study: 31471180

Group type: EXPERIMENTAL
Intervention: TXA plus topical and intravenous CSS (Group A)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: TXA plus topical CSS only (Group B)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: TXA plus intravenous CSS only (Group C)
Number of subjects: 200

Group type: COMPARATOR
Intervention: TXA only (Group D)
Number of subjects: 200
Study: 30939531

Group type: EXPERIMENTAL
Intervention: Plasma cystatin C levels before ART
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma cystatin C levels during 48 weeks of ART
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cystatin C levels with asymptomatic NCI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cystatin C levels with mild neurocognitive disorder or HIV-associated dementia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cystatin C levels with mild impairment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cystatin C levels with moderate or severe impairment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cystatin C as a diagnostic marker for NCI
Number of subjects: 0
Study: 28396863

Group type: EXPERIMENTAL
Intervention: Ultrasound/MRI fusion guided SSPS technique
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ultrasound guided SSPS technique
Number of subjects: 26
Study: 27521928

Group type: EXPERIMENTAL
Intervention: Intrauterine administration of autologous PBMCs activated by HCG (n=93)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (ET without intrauterine administration) (n=105)
Number of subjects: 240
Study: 24569051

Group type: EXPERIMENTAL
Intervention: Amizate® (3g/day)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Amizate® (6g/day)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Chocolate drink (control)
Number of subjects: 438
Study: 21836029

Group type: EXPERIMENTAL
Intervention: Satavaptan
Number of subjects: 1200
Study: 20055695

Group type: EXPERIMENTAL
Intervention: Twice-weekly tacrolimus ointment
Number of subjects: 349

Group type: COMPARATOR
Intervention: Standard treatment (vehicle ointment)
Number of subjects: 349
Study: 18546661

Group type: EXPERIMENTAL
Intervention: Non-visual pointing responses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pointing with eyes open
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verbal azimuth estimates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Using the pointer to match egocentric target azimuth
Number of subjects: 0
Study: 16457481

Group type: EXPERIMENTAL
Intervention: Valerian farmers
Number of subjects: 75
Study: 12687657

Group type: EXPERIMENTAL
Intervention: Parametric analysis of covariance with homogeneous slopes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: t-test on difference scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hierarchical approach with tests for homogeneity of regression slopes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parametric analysis of covariance with non-homogeneous slopes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two independent samples t-test on difference scores
Number of subjects: 0
Study: 10472824

Group type: EXPERIMENTAL
Intervention: Position of 90 degrees of flexion
Number of subjects: 25

Group type: COMPARATOR
Intervention: Position of 45 degrees of flexion
Number of subjects: 25
Study: 8744659

Group type: EXPERIMENTAL
Intervention: CSE analgesia with a single subarachnoid injection of 1 mg bupivacaine plus 5 micrograms sufentanil and 25 micrograms epinephrine (total volume, 2.5 mL)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: CSE analgesia
Number of subjects: 63

Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 63
Study: 8243872

Group type: EXPERIMENTAL
Intervention: Intranasal glucagon (1 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Subcutaneous glucagon (0.5 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intranasal glucagon
Number of subjects: 11

Group type: COMPARATOR
Intervention: Subcutaneous glucagon
Number of subjects: 11
Study: 3549893

Group type: EXPERIMENTAL
Intervention: Relaxation response technique practiced daily for four to six weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (quiet sitting for comparable periods without relaxation response)
Number of subjects: 0
Study: 31318121

Group type: EXPERIMENTAL
Intervention: Standard teaching plus further tuition involving a DRE volunteer (intervention group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard teaching (control group)
Number of subjects: 48
Study: 28353023

Group type: EXPERIMENTAL
Intervention: GUM Hydral
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Biotène Oralbalance
Number of subjects: 40
Study: 26853173

Group type: EXPERIMENTAL
Intervention: Propofol TCI adding low-concentration desflurane (group PD)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Propofol TCI based (group P)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Both groups (group P and group PD)
Number of subjects: 52
Study: 24719431

Group type: EXPERIMENTAL
Intervention: Weekly text-message 'check-in' intervention
Number of subjects: 350

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 350
Study: 25951697

Group type: EXPERIMENTAL
Intervention: Vitamins A and E serum concentration in CIN patients
Number of subjects: 289

Group type: COMPARATOR
Intervention: Control group (non-oncologic gynecologic conditions)
Number of subjects: 289
Study: 22955366

Group type: EXPERIMENTAL
Intervention: Uncoated probiotic strains (5×10⁹ cfu/strain/d for 21 days)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Microencapsulated probiotic strains (1×10⁹ cfu/strain/d for 21 days)
Number of subjects: 53
Study: 19574441

Group type: EXPERIMENTAL
Intervention: lovastatin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: rhAPC
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 18060022

Group type: EXPERIMENTAL
Intervention: Rituximab (anti-CD20 monoclonal antibody)
Number of subjects: 0
Study: 15138160

Group type: EXPERIMENTAL
Intervention: Photochemically treated platelets (PCT)
Number of subjects: 645

Group type: COMPARATOR
Intervention: Conventional platelets (control)
Number of subjects: 645
Study: 12492100

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (GleevecTM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon-alpha and cytarabine
Number of subjects: 0
Study: 9664766

Group type: EXPERIMENTAL
Intervention: Clonidine (5 micrograms/kg) orally
Number of subjects: 30

Group type: COMPARATOR
Intervention: Atropine sulfate (0.01 mg/kg) and hydroxyzine hydrochloride (1mg/kg) intramuscularly
Number of subjects: 30
Study: 8565037

Group type: EXPERIMENTAL
Intervention: Oxaprozin 1200 mg once daily
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Nabumetone 1000 mg once daily
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study: 2014945

Group type: EXPERIMENTAL
Intervention: PEU‐Vialon catheter
Number of subjects: 1054

Group type: COMPARATOR
Intervention: FEP‐Teflon catheter
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Prolonged catheterization (greater than 48 hours)
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Catheter-related infection
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Phlebitis with a previous catheter
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Anatomic site (hand: forearm)
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Anatomic site (wrist: forearm)
Number of subjects: 1054
Study: 7082151

Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ballistic
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Static
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Hamstrings
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Trunk
Number of subjects: 43
Study: 31863182

Group type: COMPARATOR
Intervention: Comprehensive multicomponent behavioral treatment (Beh)
Number of subjects: 579

Group type: COMPARATOR
Intervention: Combination of behavioral treatment and medication management (Comb&MedMgt)
Number of subjects: 579

Group type: COMPARATOR
Intervention: Combination treatment (Comb)
Number of subjects: 579
Study: 28701360

Group type: EXPERIMENTAL
Intervention: Early resumption of non-contact physical activity beginning 72 hours postinjury
Number of subjects: 350

Group type: COMPARATOR
Intervention: Rest until fully asymptomatic
Number of subjects: 350
Study: 28244952

Group type: EXPERIMENTAL
Intervention: Prophylactic phenylephrine infusion
Number of subjects: 506

Group type: COMPARATOR
Intervention: Vasopressor bolus strategy (Control)
Number of subjects: 506
Study: 25526101

Group type: EXPERIMENTAL
Intervention: 27‐gauge transconjunctival nonvitrectomizing vitreous surgery (NVS)
Number of subjects: 83

Group type: COMPARATOR
Intervention: 25‐gauge transconjunctival sutureless vitrectomy surgery (Standard)
Number of subjects: 83
Study: 25015006

Group type: EXPERIMENTAL
Intervention: Clonidine 5 μg/kg every 6 hours
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 22982947

Group type: EXPERIMENTAL
Intervention: Peer-led education program on HIV prevention
Number of subjects: 276
Study: 19568195

Group type: COMPARATOR
Intervention: Inactive control
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low-amount/moderate-intensity and low-amount/vigorous-intensity
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High-amount/vigorous-intensity
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low-amount groups combined
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High-amount group
Number of subjects: 50
Study: 17689632

Group type: EXPERIMENTAL
Intervention: Simulated shoulder dystocia
Number of subjects: 140
Study: 15226624

Group type: EXPERIMENTAL
Intervention: Argatroban
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study: 11273845

Group type: EXPERIMENTAL
Intervention: Structured triacylglycerol
Number of subjects: 35

Group type: COMPARATOR
Intervention: Cocoa butter
Number of subjects: 35

Group type: COMPARATOR
Intervention: High-oleate sunflower oil (oleate)
Number of subjects: 35
Study: 9883467

Group type: EXPERIMENTAL
Intervention: 5 million units of interferon alpha-2b
Number of subjects: 75

Group type: COMPARATOR
Intervention: 3 million units of interferon alpha-2b
Number of subjects: 75
Study: 7983296

Group type: EXPERIMENTAL
Intervention: Telephone administration of SF-36
Number of subjects: 100

Group type: COMPARATOR
Intervention: Face-to-face administration of SF-36
Number of subjects: 100
Study: 1753728

Group type: EXPERIMENTAL
Intervention: Flexibility training (3 times per week, 20-30 minutes for 10 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no training, alternative exercise program including walking, swimming, dance, and other locomotor activities)
Number of subjects: 20
Study: 7019928

Group type: EXPERIMENTAL
Intervention: Sisomicin (2.5 to 4.0 mg/kg per day for 5 to 21 days)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Tobramycin (2.5 to 4.0 mg/kg per day for 5 to 21 days)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Sisomicin
Number of subjects: 55

Group type: COMPARATOR
Intervention: Tobramycin
Number of subjects: 55
Study: 30811909

Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Number of subjects: 647

Group type: COMPARATOR
Intervention: No lymphadenectomy
Number of subjects: 647
Study: 29344387

Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection (RCI) 40 U daily or 80 U every other day for 8 weeks, followed by open-label extension with 16, 40 or 80 U RCI 1-3 times/week for 52 weeks.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo for 8 weeks, followed by RCI in the open-label extension.
Number of subjects: 38
Study: 26095443

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitative care (task-oriented exercises, cognitive-behavioral training, and occupational therapy)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitative care
Number of subjects: 70

Group type: COMPARATOR
Intervention: General physiotherapy (control)
Number of subjects: 70
Study: 23702855

Group type: EXPERIMENTAL
Intervention: 90° shoulder abduction with elbow extension (90 ABD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 130° shoulder abduction with elbow flexion at 110° (130 ABD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 150° shoulder abduction with elbow extension (150 ABD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 170° shoulder abduction with elbow extension (170 ABD)
Number of subjects: 60
Study: 21237455

Group type: EXPERIMENTAL
Intervention: CO(2) insufflation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 40
Study: 18069061

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study: 17415652

Group type: EXPERIMENTAL
Intervention: Antiviral therapy (including interferon monotherapy, pegylated-interferon monotherapy, consensus-interferon, interferon + ribavirin, pegylated-interferon + ribavirin)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Antiviral therapy
Number of subjects: 56
Study: 15234664

Group type: EXPERIMENTAL
Intervention: 15% paromomycin plus 12% methylbenzonium chloride (PR‐MBCL) applied twice daily for 30 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 15% paromomycin plus 10% urea (PR‐U) applied twice daily for 30 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: 20mg/kg/day of IM meglumine antimoniate (MA) for 10 days
Number of subjects: 120
Study: 11398169

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors as second-line therapy for postmenopausal women with advanced breast cancer progressing during tamoxifen therapy.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors as first-line therapy in place of tamoxifen.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors in the prevention of breast cancer and in neoadjuvant and adjuvant treatment of early-stage breast cancer.
Number of subjects: 0
Study: 9533048

Group type: EXPERIMENTAL
Intervention: Twisted autograft (90 degrees of external twist)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nontwisted autograft (control)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups (twist and control)
Number of subjects: 120
Study: 7989475

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment for 4 months; mean BMI of treated subgroup: 42.7 ± 4.3 kg/m2.
Number of subjects: 31
Study: 3044515

Group type: EXPERIMENTAL
Intervention: Mosquito nets
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Proguanil hydrochloride (100 mg daily according to weight)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo (1 or 2 tablets daily)
Number of subjects: 190
Study: 31126123

Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (starch)
Number of subjects: 32
Study: 29202258

Group type: EXPERIMENTAL
Intervention: Early goal-directed sedation using dexmedetomidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual practice (standard care)
Number of subjects: 0
Study: 26159436

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided radial artery catheterization
Number of subjects: 125

Group type: COMPARATOR
Intervention: Direct palpation radial artery catheterization
Number of subjects: 125
Study: 23419341

Group type: EXPERIMENTAL
Intervention: GlideScope videolaryngoscope
Number of subjects: 30

Group type: COMPARATOR
Intervention: Macintosh direct laryngoscope
Number of subjects: 30
Study: 21198772

Group type: EXPERIMENTAL
Intervention: Propofol (0.35 mg kg(‐1))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam (0.035 mg kg(‐1))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketamine (0.30 mg kg(‐1))
Number of subjects: 0
Study: 18220290

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a plus oral placebo for 48 weeks
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Number of subjects: 271

Group type: COMPARATOR
Intervention: HBV DNA
Number of subjects: 271
Study: 16154709

Group type: EXPERIMENTAL
Intervention: PTSD patients
Number of subjects: 63

Group type: COMPARATOR
Intervention: Non-PTSD subjects
Number of subjects: 63

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Overall cortisol secretion (AUC(G))
Number of subjects: 63
Study: 14583678

Group type: EXPERIMENTAL
Intervention: Loperamide (24 mg) with Quinidine (800 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Loperamide (24 mg) without Quinidine (placebo)
Number of subjects: 20
Study: 10975630

Group type: EXPERIMENTAL
Intervention: Alcohol (0.62 g/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9383184

Group type: EXPERIMENTAL
Intervention: 240 mg sustained-release verapamil
Number of subjects: 1414

Group type: COMPARATOR
Intervention: 25 mg chlorthalidone
Number of subjects: 1414
Study: 1388337

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg IV)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Droperidol (1.25 mg IV)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Metoclopramide (10 mg IV)
Number of subjects: 66
Study: 3890014

Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 33

Group type: COMPARATOR
Intervention: Hypaque (diatrizoate sodium and diatrizoate meglumine)
Number of subjects: 33
Study: 29909432

Group type: EXPERIMENTAL
Intervention: Sublingual administration of 50 mg sildenafil
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Supralingual administration of 50 mg sildenafil
Number of subjects: 12
Study: 27590190

Group type: EXPERIMENTAL
Intervention: Major PAD
Number of subjects: 11140

Group type: EXPERIMENTAL
Intervention: Lower-extremity ulceration or amputation
Number of subjects: 11140
Study: 24141253

Group type: EXPERIMENTAL
Intervention: Bed and bedside chair pressure sensors using radio-pagers
Number of subjects: 1839

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1839
Study: 22776958

Group type: EXPERIMENTAL
Intervention: High-dose recombinant human erythropoietin (rEpo) 3 × 3,000 U/kg within 42 h after birth
Number of subjects: 0
Study: 21147867

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Bevacizumab + Irinotecan (CPT-11)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) and Bevacizumab + Irinotecan (CPT-11)
Number of subjects: 167
Study: 17432275

Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin (LMWH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin K Antagonists (VKAs)
Number of subjects: 0
Study: 16109111

Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg plus naproxen sodium 500 mg
Number of subjects: 972

Group type: COMPARATOR
Intervention: Sumatriptan 50 mg
Number of subjects: 972

Group type: COMPARATOR
Intervention: Naproxen sodium 500 mg
Number of subjects: 972

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 972
Study: 12324670

Group type: EXPERIMENTAL
Intervention: Proportional assist ventilation (PAV) during exercise training
Number of subjects: 19

Group type: COMPARATOR
Intervention: Unaided exercise training
Number of subjects: 19
Study: 10457687

Group type: EXPERIMENTAL
Intervention: AR-coated lenses (Crizal)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Uncoated lenses
Number of subjects: 19
Study: 7593498

Group type: EXPERIMENTAL
Intervention: Humegon (225 IU)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Pergonal (225 IU)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Both preparations
Number of subjects: 9
Study: 1701802

Group type: EXPERIMENTAL
Intervention: Continuous therapy with recombinant interferon gamma (4 X 10(6) I.U. daily, 3 injections/week for 13 weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intermittent block therapy with recombinant interferon gamma (4 X 10(6) I.U. daily, 4 cycles of 5 injections on days 1, 3, 5, 7, and 9)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intermittent single-dose therapy with recombinant interferon gamma (4 X 10(6) I.U. daily, 6 cycles of 1 injection on day 1)
Number of subjects: 12
Study: 6988175

Group type: EXPERIMENTAL
Intervention: 50 mg nitrofurantoin plus 150 mg sulphadiazine 3-times daily
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: 100 mg nitrofurantoin plus 500 mg sulphadiazine 3-times daily
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Lower dosage group (50 mg nitrofurantoin plus 150 mg sulphadiazine)
Number of subjects: 177
Study: 31983583

Group type: EXPERIMENTAL
Intervention: Performance-Based Financing (PBF) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health facilities receiving intensified Polio Eradication Initiative (PEI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unconditional financial and technical assistance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PBF intervention
Number of subjects: 0
Study: 31176392

Group type: EXPERIMENTAL
Intervention: Modified SAE implants (test group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: SAE implants (control group)
Number of subjects: 20
Study: 28642466

Group type: EXPERIMENTAL
Intervention: Cognitive dual task gait training (CDTT)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Motor dual task gait training (MDTT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional physical therapy (CPT)
Number of subjects: 28
Study: 25586372

Group type: EXPERIMENTAL
Intervention: i-gel prewarmed to 42°C (W group)
Number of subjects: 74

Group type: COMPARATOR
Intervention: i-gel kept at room temperature (C group)
Number of subjects: 74